General meetings

February 23, 2024

Extraordinary General meeting

Date: February 23, 2024 1:00 pm
Where: Gullhaugveien 7, Oslo / Virtual

Additional info:

For virtual participation please use the following LINK

The auditors report is avialable HER


May 2, 2023

Annual General meeting

Date: May 2, 2023 5:00 pm
Where: Gullhaugveien 7, Oslo / Virtual

April 20, 2022

Annual General Meeting

Date: April 20, 2022 12:00 pm
Where: Gullhaugveien 7, Oslo

February 4, 2022

Extraordinary General meeting

Date: February 4, 2022 2:00 pm
Where: Digital participation

July 2, 2021

Extraordinary General meeting

Date: July 2, 2021 2:00 pm
Where: Digital participation

April 26, 2021

Annual General Meeting

Date: April 26, 2021 1:00 pm
Where: Digital participation

May 20, 2020

Extraordinary General meeting

Date: May 20, 2020 2:30 pm
Where: Digital participation / Gullhaugveien 7, Oslo

April 22, 2020

Annual General Meeting

Date: April 22, 2020 12:00 pm
Where: Gullhaugveien 7, Oslo (Office of Oncoinvent AS)

April 30, 2019

Annual General Meeting

Date: April 30, 2019 3:00 pm
Where: Radisson Blu Nydalen

April 24, 2018

Annual General Meeting

Date: April 24, 2018 3:00 pm
Where: Radisson Blue Nydalen

March 14, 2017

Annual General Meeting

Date: March 14, 2017 3:00 pm
Where: Radisson Blu Nydalen

Anders Månsson

Chief Executive Officer

mansson@oncoinvent.com

Anders Månsson is a business executive with over 25 years of experience from management roles in the pharmaceutical industry, focusing on commercialisation and M&A + licensing. Mr. Månsson has held leading roles in the industry both in his native Sweden and in other European countries, and he has worked extensively with the USA and Asia as focus markets in global roles.

Mr. Månsson holds a B.Sc. degree in Business & Economics from Lund’s University in Sweden as well as an MBA from Business School Lausanne in Switzerland. He has a broad-based industrial experience, featuring both large multinational companies such as Meda, Ferring & LEO Pharma, and including leading roles in start-ups and smaller biotech companies. On top of his executive role in Oncoinvent, Mr. Månsson holds two non-executive director positions serving on the board of EQL Pharma AB as well Immetric AB, the latter being an investment company focusing on life science.